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ABSTRACT
Introduction: Alzheimer’s disease (AD) is the most common form of dementia
and an estimated 5.7 million American’s are currently suffering from this disease
resulting in $277 billion in health care costs as of 2018. As the number of cases and cost
are expected to double by 2050, new approaches are needed to properly identify at-risk
individuals prior to irreversible changes to the brain caused by this disease. Purpose:
Through the use of a novel rodent model, this study assessed early changes in muscular
coordination and strength relative to cognitive decline due to AD, as well as providing
insight into the progression of these changes and whether sex differences exist within AD
development. Hypothesis: Declines in muscular coordination and strength will precede
cognitive decline. Males will exhibit significantly worse declines among all measures
earlier than females. Methods: Thirty-eight TgF-344AD rats were compared to 38 wild
type (WT) TgF-344 rats for muscle atrophy (grip strength test), coordination (rotarod),
and spatial memory (Morris Water Maze test). Testing periods occurred at 3, 6, and 9 m
and body weight was measured prior to assessments for these time periods. Statistical
Analysis: Repeated measures ANOVA was used to identify within group differences.
Mixed model 2-way ANOVA (group x age) with a Bonferroni post hoc test was used to
identify any significant effects. ANOVA with a Tukey post hoc was used to determine
between group differences. Unpaired independent T-tests were used to determine the
degree of significance based on significant P-values (p≤0.05) determined by the Tukey
post hoc test. Results: AD males displayed significantly heavier body weight at 3 m, 6 m,
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and 9 m and AD females displayed significantly heavier body weight at 6 m and 9 m
compared to the WT cohort. No significant difference was seen in grip strength between
any groups. AD females and AD males expressed a significant decline in motor
coordination at 6 m but by 9 m all groups expressed a significant decline in motor
coordination. No significant difference was seen in motor coordination between groups.
The AD group as a whole displayed significantly worse memory function at 9 m
compared to WT group. Conclusion: Body weight may be a risk factor for developing
AD. AD may cause an accelerated rate of decline in motor coordination. Memory
dysfunction precedes deficits in strength and coordination. No AD-related sex differences
were identified but 2-way ANOVA identified a significant effect for AD females on
motor coordination decline seen at 6 m but not males.
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CHAPTER ONE: INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia accounting for
60-80% of all cases. An estimated 5.7 million Americans are suffering from AD and that
number is expected to rise to 14 million by 2050 (Alzheimer’s Association, 2018). The
estimated total cost for these individuals and their families is $277 billion for 2018. The
number of cases and cost is estimated to double over the next 50 years as there is no current
treatment to cure or slow the progression of this disease. Although AD is typically
associated with aging, an estimated 200,000 of the 5.7 million cases develop AD before
reaching age 65.
Currently there is no cure or treatment to slow AD disease progression. However,
in addition to finding treatments, research is needed to improve the diagnosis of AD. AD
is commonly identified in patients by memory loss, cognition and behavior alterations.
Patient’s suffering from previously mentioned symptoms will undergo a functional
magnetic resonance imaging (fMRI) of their brain. If these tests reveal Amyloid beta (Aβ)
plaques and neurofibrillary tangles (NFTs) with brain atrophy they will be diagnosed with
AD. Prior to diagnosis, elderly subjects who develop AD present significantly lower
cognition and memory capabilities when compared to elderly subjects who do not develop
AD (Baker et al., 2010; Verghese et al., 2003). Recently, AD has also been strongly
correlated with declines in muscular strength and motor control (Roberts et al., 2013;
Taekama et al., 2012). These strong and well documented correlations could provide an
avenue for diagnostic tools as well as elevating our understanding of AD progression.
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Natural aging induces muscle and brain atrophy (Pollack, Phaneuf, Dirks, &
Leeuwenburgh, 2002); however, there are subtle yet key differences between natural aging
and AD development. While regions of the brain impacted with age and AD are the same,
the rates and patterns of muscle atrophy can identify individuals who have AD or are at
risk of developing AD. This, with more research, will likely lead to better diagnostic
practices. Biomarkers Aβ and modified tau in the form of NFTs also distinguish AD from
natural aging. In AD, Aβ and modified tau accumulate in the centers of the brain
responsible for learning and memory leading to synapse loss and death, which ultimately
leads to impaired cognition and memory. This study will aim to identify physiological
changes (i.e., memory, motor coordination, and skeletal muscular strength) pre-onset of
the development of the pathological cascades.
Current rodent models genetically modified to exhibit AD are problematic in that
they only exhibit a part of the AD pathogenesis and do not fully recapitulate human AD
pathology. For example, transgenic rat models modified to overexpress Aβ may only
exhibit this side of AD development without the presence of NFTs, which are a key feature
of human AD. However, a new transgenic model is available, TgF344-AD, which displays
the complete repertoire of AD pathological features, including, age-dependent
accumulation of cerebral amyloid-β that preempts tauopathy, cognitive disturbance,
apoptosis, and neuronal loss. (Cohen et al., 2013; Joo et al., 2016; Pentkowski et al., 2018;
Munoz-Moreno et al., 2018; Rorabaugh et al., 2017; Smith, & McMahon, 2018; Tsai et al.,
2013; Vorhees et al., 2018). Nine studies have been conducted to date with this model;
however, it promises to be a viable model to use for AD research. This study will be the
first to analyze skeletal muscle strength and motor control employing this rat model of AD.
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Research has identified gender differences in AD progression (Burke et al., 2018;
Nead et al., 2015; Phung et al., 2010), which has been confirmed using rodent models
(Carroll e. al., 2010; Munetumo et al., 2015; Woolley, & McEwen, 1992). The dichotomy
of gender-differentiated AD progression is due to sex hormone interaction in neuronal
growth and repair (Cacciottolo et al. 2016; Rosario, Chang, Head, Stanczyk, & Pike, 2011).
The primary hormones used for neuronal growth for females is estradiol and testosterone
for males. The difference in hormonal decline between genders due to aging and the use of
estradiol versus testosterone relates to differences in Aβ load, brain region affected, and
rate of cognitive decline in AD progression (Cacciottolo et al., 2016; Carroll et al., 2010).
These differences suggest that males exhibit more abrupt cognitive impairment earlier in
life than females but it eventually plateaus. Females; however, exhibit a gradual decline
and show worse performances on cognitive tests at later time points in life than males
(Burke et al., 2018; Carroll et al., 2010). This study, accordingly, will analyze these gender
differences in the development of AD. Understanding this dichotomy will aid in the
effectiveness of diagnosing and treating individuals.
The primary hypothesis of this study is muscular coordination and strength declines
in Alzheimer’s disease and these muscular changes will precede memory declines. The
secondary hypothesis is males will exhibit significantly worse performances on all
parameters being tested at the 9m test period. Research indicates that males express more
drastic declines in cognition earlier than females due to differences in hippocampal volume
and Aβ load, which may be the result of differences in sex hormones (Burke et al., 2018;
Carroll et al., 2010; Irvine, Laws, Gale, & Kondel, 2012; Leranth, Pentnehazy, &
Maclusky, 2003; Nead et al., 2015). Muscle strength and coordination will be assessed by
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a grip strength test and rotarod test (Bioseb, Panlab), respectively. Spatial memory will be
assessed using a Morris Water Maze test (Voorhees, & Williams, 2006). The first aim of
this study is to enhance the protocol for identifying AD or risk of developing AD among
humans using physiological tests such as strength and motor control tests. The second aim
is to validate the rotarod test in an AD rat model. The third and final aim is to identify sex
differences among the development of AD: previous studies have indicated males tend to
exhibit a steeper decline in cognition earlier, whereas females exhibit a steady decline and
exhibit a steeper decline as AD progresses overall (Carroll et al., 2010).
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CHAPTER TWO: LITERATURE REVIEW
The Effect of Exercise on the Progression of Alzheimer’s Disease
Exercise can slow the rate of cognitive decline among individuals suffering from
AD; even general physical activity and higher fitness levels decrease risk of AD (Best,
Chiu, Hsu, Nagumatsu, & Liu-Ambrose, 2015; Maass et. al, 2015; Matura et al., 2017;
Nagumatsu et al., 2013; Voss et al., 2013). Nouchi et al. (2014) studied the effects of shortterm exercise on cognitive functions among 64 healthy subjects over the age of 62. The
exercise intervention consisted of interval training and strength training at 60-80% of their
maximum heart rate for 24 minutes 3 days a week for 4 weeks (Nouchi et al., 2014), while
the control group was asked to refrain from exercise during this 4-week period. Cognitive
function was measured across six categories: executive function, episodic memory,
working memory, reading ability, attention, and processing speed. The results indicated
that subjects receiving the intervention improved on all measures of executive function,
processing speed, and one measure of episodic memory (logical memory), which suggests
exercise can improve cognitive function. Although this study did not include outcome
measures of muscular strength or cardiovascular output other studies have identified
improvements between these measures and improved cognitive function and brain
plasticity (Baker et al., 2010; Chan et al., 2005; Chapman et al., 2016; Nagumatsu et al.,
2016; Voelcker-Rehage, Godde, & Staudinger, 2011). For example, Baker et al.
demonstrates that aerobic exercise intervention improves 𝑉𝑉̇ O2peak and cognitive function
among 33 subjects suffering from mild cognitive impairment (MCI). MCI is a termed used
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to identify individuals who are experiencing cognitive decline greater than expected for
their age but does not interfere with daily activities (Gauthier et al., 2006). 𝑉𝑉̇ O2peak is a
measure of a person’s capacity for aerobic ATP synthesis (McArdle, Katch, & Katch,

2010). This study used the modified Balke maximal-graded exercise treadmill test, which
maintains a constant speed but increases 1% grade every minute (McArdle, Katch, &
Katch, 2010). Higher 𝑉𝑉̇ O2peak values indicate higher fitness levels and vice versa for lower

𝑉𝑉̇ O2peak values. Improvements in cognitive function due to the aerobic training was greatest

among women. Furthermore, changes in 𝑉𝑉̇ O2peak among women was correlated with

improved glucoregulation and insulin sensitivity and changes in insulin sensitivity
predicted 𝑉𝑉̇ O2peak and executive function. Exercise is commonly used to treat diabetic (type
II) patients but can be extended as a prevention measure among individuals at risk for AD
(Umpierre et al., 2011). Being that glucose is the primary source of energy for the brain,
these results suggest that MCI and AD may cause a dysfunction among glucose uptake,
which exercise can remedy by changes made centrally (brain) or peripherally (muscle).
Exercise Increases Brain Volume and Function
Exercise has also been shown to increase brain volume with aging and stabilize
brain atrophy associated with AD (Erickson et al., 2009; 2010; 2011; Burns et al., 2008),
which correlates to an enhancement of brain function, as measured with MRI and a spatial
memory task (Voss et al., 2010; 2013). A study involving healthy and AD subjects between
the ages of 59-81 years old identified a significant correlation between fitness level
measured by VO2peak and hippocampus size. The individuals with higher cardiorespiratory
fitness express larger hippocampus size, which correlated with better scores on the spatial
memory assessment (Erickson et al., 2009). To understand whether AD impacts fitness
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level, the next logical step was to analyze the impact of an exercise regimen on brain
volume among individuals with AD. Erickson et al. implemented a 12-month walking
program among a similar population and found that aerobic exercise increases
hippocampus size, which correlates with significant improvements in spatial memory
(Erickson et al., 2011). As these improvements are a result of exercise, Voss et al. (2010)
indicates that connectivity between brain regions improves with exercise. Improved
connectivity was indicated by functional MRI scans showing an increase in activity
between the bilateral parahippocampus and the bilateral middle temporal gyrus post
exercise intervention. Altogether these studies indicate that exercise increases brain volume
which produces better connectivity between regions resulting in improvements in cognition
among patients suffering from AD. Furthermore, exercise is used to treat people suffering
from obesity, hypertension, and type II diabetes which are common risk factors for
dementia (Baumgart et al., 2015; Chatterjee et al., 2016). This extends the notion that
exercise may play an important role in maintaining one’s brain health.
Exercise-Induced Changes in Aβ/tau are Unknown
Aβ plaque and NFTs are important hallmarks to AD and the pathogenic
development of these proteins are described in a latter section but again there is evidence
suggesting exercise can be used to alleviate symptoms caused by these brain lesions. Using
an AD transgenic mouse model, Ke et al. (2011) implemented an aerobic exercise protocol,
which consisted of treadmill running 5 days a week for 1 month. For the first week, the
mice ran for 10 min/day; by the second week training time increased 10 min every day
until 60 min of continuous running was achieved and was maintained for the remainder of
the intervention. Results of this study indicated that Aβ40 and Aβ42 levels were
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significantly reduced by exercise but had no effect on plaque formation (Ke, Huang, Liang,
& Hsieh-Li, 2011). These results are potentially confounding because Aβ40 and Aβ42 are
typically precursors to plaque formation; however, as mentioned below there are other Aβ
substituents that can cause plaque formation as well. These results differ from other studies
involving different AD transgenic mice (Adlard, Perreau, Pop, Cotman, 2005; Yuede et al.,
2009). Therefore, when examining the impact of exercise, it may be dependent upon which
model is employed. Overall, there does appear to be a correlation between exercise and
improving brain health. For example, one study indicates a reduction in plaque formation
as well as a reduction Aβ40 and Aβ42 formation induced by exercise. This study used the
TgCRND8 mouse line (Adlard et al., 2005), whereas the previous study used an amyloid
precursor protein/presenilin 1 (APP/PS1) mouse model. In the Adlard et al. (2005) study,
the authors overexpressed a double mutant form of the APP gene, which only incorporated
the Aβ arm of AD pathogenesis, whereas the Ke et al. (2011) model expressed both Aβ
and tau formation. The importance of the model employed is described below but mouse
models do not express the same similarities in genome in comparison to rats as they relate
to the human genome with rats being a better match to the human genome and development
and progression of AD. Furthermore, the few studies that have addressed the impact
exercise has on NFTs are promising as these reports show a suppression of NFTs caused
by exercise (Belrabi et al., 2011; Leem et al., 2009; Um et al., 2011). These reports used
models expressing NFTs without the expression of Aβ plaques, which based on the Aβ
hypothesis, Aβ plaques are a necessary component in the development of neurotoxic tau
during human pathogenesis of AD. Regardless of the differences among these models and
the human development of AD, muscle plasticity seems to play an important role in the
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development of AD and future research should be directed towards identifying the
mechanisms involved that lead to improved brain health.
Development of Alzheimer’s Disease
The development of AD progresses with age and is typically identified by cognitive
decline and memory loss. The progressive loss of cognitive function is usually identified
behaviorally using tests like the Mini-Mental State Examination (MMSE). However,
scientists can detect changes in cognition and brain atrophy by testing the motor control of
elderly individuals because motor function is a measurable output of central and peripheral
nervous systems (Allali, Annweiler, Pedrovan, Bherer, & Beauchet, 2016; Beauchet,
Launay, Annweiler, & Allali, 2015; Buchman, Wilson, Boyle, Bienias, & Bennett, 2007b;
Callisaya et al., 2013; Macdonald et al., 2017). As a result of declining motor control,
elderly individuals have less control over their movements resulting in falls and the
inability to complete normal household chores (activities of daily living, ADLs), which
leads them to perform fewer physical activities further progressing the loss of muscular
strength, which further exacerbates declines in motor control, falls, and ADLs. This
connection provides the basis for examining the muscular strength and correlating strength
to declines in cognition.
Alzheimer’s Disease Leads to Declines in Muscular Strength and Motor Control
Grip strength tests are easily employed and widely used to assess muscular strength
among the elderly. Recent studies have correlated muscular strength assessed by the grip
strength tests with age, height, weight, cognitive ability, MCI to AD development, motor
control, and mortality (Boyle et al., 2010; Buchman, Wilson, Boyle, Bienias, & Bennett,
2007a; Roberts et al., 2013; Sternäng et al., 2015; Taekema et al., 2012). The progression
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from MCI to dementia is unclear; however, research indicates 88% of people with MCI
and reduced memory function will develop dementia within 3 years (Olichney et al., 2008).
Another study suggests that 50-70% of individuals with MCI and high Aβ loads will
develop dementia within 5-7 years (Drago et al., 2011) The majority of these studies
assessed grip strength and its correlation with cognitive decline and found that muscular
strength is a controllable factor that can slow cognitive decline correlated to AD. That is,
strength and motor function starts to decline before the onset of cognitive impairment,
which may contribute to the onset of dementia. One such study performed by Boyle et al.
(2010) looked at the correlation between physical frailty, MCI, and progression to AD.
This study included 750 community based elderly people with no dementia or MCI from
the Rush Memory and Aging project. After analyzing the data, Boyle et al. (2010) reported
physical frailty, as defined by grip strength, timed walk, body composition, and fatigue
showed positive correlation to age and negative correlation to education and global
cognitive function (Boyle et al., 2010). Increasing frailty correlated with normal aging;
however, 40% of the population who developed MCI expressed higher levels of frailty at
baseline (Boyle et al., 2010). In this context, dementia enhances the rate of frailty more so
than normal aging but increased frailty at baseline could be an early indicator of dementia,
which is why people who developed MCI had higher baseline frailty scores than those who
did not develop MCI. By eliminating the possible confounding variables, such as age, sex,
and education, Boyle, et al., found that baseline frailty is correlated with an even greater
risk of developing MCI, further enhancing the relationship between these two variables.
This study also indicated that demographic characteristics do not impact the correlation
between frailty and MCI. Development of MCI is reversible but individuals who express
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persistent MCI correlated with weaker grip strength, whereas as frailty as a whole
correlated with first occurrence of MCI (Boyle et al., 2010). This study also indicates
higher levels of physical frailty correlated to lower global cognition and more rapid decline
in global cognition as measured by MMSE (Boyle et al., 2010). There is a clear correlation
between cognitive function and physical parameters such as muscle strength and motor
control. However, identifying what happens first in the pathogenesis of AD is highly
debated but the prevailing view is that a decline in physical ability may precede the
cognitive decline observed in AD ((Alfaro-Acha et al., 2006; Buchman et al., 2007b; Gray
et al., 2013).
Sternäng et al. (2015) analyzed grip strength and multiple parameters of cognitive
function such as verbal ability, spatial ability, processing speed, and memory. The results
of the study indicated significant unidirectional correlations between grip strength and
verbal/spatial ability and memory. Whereas, the relationship between grip strength and
processing speed shows a bidirectional correlation. This suggests that the decline in
muscular strength impacts certain parameters of cognitive function and vice versa. Other
investigations indicate that muscular strength relates to the rate of cognitive decline and
motor performance (Buchman et. al, 2007a; Roberts et. al, 2013). However, Taekema et
al’s. (2012) findings suggest the opposite, cognitive decline impacts the decline in
muscular strength. In the Taekema et al. (2012) study, the authors only used elderly
individuals between 85-89 years of age, whereas Sternäng et al. (2015) investigated these
parameters among individuals ranging from age 40-86 years. Sternäng et al. (2015) found
that decline in strength and cognition do not significantly change until 65 years of age. If
this is true, Taekema et al. (2012) subjects had 20+ years of muscular and cognitive decline,
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so these findings might be only generalizable to individuals who are among the oldest of
old in a population.
While it is well documented that strength and coordination decline with age, the
question remains whether declines seen with AD are independent of age. The brain regions
affected by aging and AD directly affect motor control with AD causing the greatest
reductions in brain volume and motor control. The specific regions of the brain most
impacted by AD are hippocampus, amygdala, entorhinal cortex, parietal lobe, and the basal
ganglia (Beheshti, Demirel, & Alzheimer’s Disease Neuroimaging Iniative 2016; Cai et.
al, 2018; Davatzikos, Bhatt, Shaw, Batmanghelich, & Trojanowski, 2011; Misra, Fan, &
Davatzikos, 2009; Nagumatsu et al., 2016). As information is received by a person’s
senses, the sensory input is distorted by alterations in these brain regions and this further
distorts one’s response, which is reflected by the coordination of the movement.
Determining the region of the brain that is the base of all the AD-related problems is
extremely difficult. However, if the first AD-associated decline is in one’s motor control
that would suggest the formation of AD begins in the basal ganglia. Nagamatsu et al. (2016)
identified that increasing mobility correlated with little to no change in putamen volume
(structure of basal ganglia) and the decline in mobility significantly correlated with this
part of the basal ganglia. This study only analyzed healthy elderly individuals but Cai et al.
(2018) confirmed that feeder and local connection strength in the basal ganglia is
significantly lower among subjects suffering from AD compared to healthy elderly. This
disruption will be further analyzed in the following sections addressing the proteins
associated with neuronal connectivity and volume decline.
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Both Amyloid Beta Plaque and Tau Protein Tangles Play a Significant Role in AD
There are many hypotheses to explain the pathogenesis of AD: cholinergic
hypothesis, tau hypothesis, inflammation hypothesis, and amyloid (Aβ) hypothesis. The
most prominent hallmark to AD is Aβ plaque formation and the progression of this
pathogenesis regardless of the hypothesis relies on the APP. Furthermore, more and more
studies have contributed evidence towards the Aβ hypothesis (Andrews-Zwilling et al.,
2010; Hansson et al., 2007; Jin et al., 2011; Kretner et al., 2016; Roberson et al., 2007;
Rapoport et al., 2002; Talantova et al., 2013; Yasojima, McGreer, & McGreer, 2001). This
section will focus on explaining the mechanisms involved in the Aβ hypothesis and the
progression of the AD pathogenic cascade.
The Aβ hypothesis was first described by Glenner and Wong (1984) and refined by
Hardy and Selkoe (2002) in their review and is depicted in Figure 1 in the appendix. The
Aβ hypothesis progresses in the following manner: missense mutations in APP and PS1
induces Aβ42 production and accumulation leading to Aβ42 oligomerization and
deposition as diffuse plaques. Aβ oligomer effects synapses leading to microglial and
astrocytic activation inducing synaptic and neuritic injury causing altered neuronal ionic
homeostasis and oxidative injury. These changes alter kinase/phosphatase activities
resulting in tau tangles and neuronal/neuritic dysfunction and cell death with transmitter
deficits ultimately leading to dementia. Below will describe how each step occurs at the
molecular level.
Research supports the aberrant cleavage of APP results in the production and
accumulation of Aβ42 and Aβ43. Although a mutation in PS2 can cause the production of
these amyloid peptides PS1 tends to have a dominant influence on the pathological cascade
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(Wolfe et al., 1999). Following the PS1 pathway, as APP produces Aβ peptides the
mutation in the PS1 causes an increased production of longer amyloid peptide Aβ42.
However, a recent study has indicated that the loss of PS1 function increases the production
of Aβ43 and is preferentially deposited in the frontal cortex and hippocampus (Kretner et
al., 2016). The APP mutant pathway is caused by microduplications of the APP gene on
chromosome 21, which ultimately causes overexpression of APP leading to higher Aβ load.
Oligomers are created by the misfolding of Aβ42 and Aβ43 and are deposited as plaques
in the brain (Bernstein et al., 2009; Klein, Krafft, & Finch, 2001; Kirkitadze, Bitan, &
Teplow, 2002). Jin et al. also identified Aβ dimers having a role in the pathogenesis of AD
but the relationship between dimers and plaques are unclear but show a correlation (Jin et
al., 2011; McDonald, Craig, & Hong, 2010). The formation of these plaques has been
identified in a variety of ways in the damage and reduction of brain tissue.
An extensive amount of research has implicated oligomer formation in the
continuous astrocytic activation. Talantova et al’s. (2013) study provided a clear picture
for this portion of the pathological cascade. This study indicated Aβ oligomers activate α7
nicotinic acetylcholine receptors (α7nAChRs) on astrocytes, which causes a release of Ca2+
inducing glutamate release. Using α7nAChR null mice and α-Bgtx (α7nAChR antagonist)
almost completely inhibits the glutamate release (Talantova et al., 2013). The increase in
glutamate is an iconic characteristic of synaptic damage, which this study indicated is
dependent on Ca2+ availability. Once glutamate is released, it activates extrasynaptic Nmethyl-D-aspartate receptors (eNMDARs). eNMDAR mediates the increase in nitric oxide
(NO), tau, hyperphosphorylated tau, and caspase-3 activity leading to synaptic damage.
The region primarily impacted was the hippocampus (Talantova et al., 2013). This study
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provided crucial information in the pathological process of AD by identifying the
hippocampus as the primary location for these events. Additionally, by identifying the
increase in NO, tau and cholinergic receptor activity as a product of Aβ oligomer
stimulation implies that inflammation, tau, and cholinergic receptors have a role in AD but
is a product encapsulated by the Aβ hypothesis. Additionally an increase in caspase-3 was
identified, which is a key protein responsible for apoptosis indicating a pathway causing
synaptic loss resulting in a decline in brain volume commonly seen in the pathogenesis of
AD. Studies such as this one implicates APP dependent hyperphosphorylation of tau (Jin,
et al., 2011; Talantova, et al., 2013; Puzzo, et al., 2017; Takahashi, et al., 2015) but other
findings suggest the neurotoxicity of Aβ oligomers are dependent on NFT expression
(Andrews-Zwilling, et al., 2010; Rapoport, et al., 2002; Roberson, et al., 2007). As some
research has shown Aβ plaque formation but no AD-like symptoms and AD pathologies
without plaque formation (Erten-Lyons et al., 2009).
To address the cognitive effects of Aβ plaque and tau expression Roberson et al.
(2007) crossed human APP (hAPP) mice with mice expressing two, one or no endogenous
tau alleles and compared these models to mice only expressing one of the three tau allele
genotypes. The results of this study indicate that mice expressing hAPP/Tau+/+ perform
significantly worse on all cognitive tests. Interestingly, the mice that were not crossed
hAPP mice perform better on these tests indicating tau expression alone did not cause
significant cognitive decline – further suggesting the pathogenesis of AD must have the
expression of both Aβ and tau. The most puzzling characteristic identified in all three hAPP
models was they all express similar neuritic dystrophy, yet mice expressing hAPP/Tau+/+
exhibit significantly more premature deaths. Denoting tau is downstream of plaque
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formation and a decline in brain tissue but cognitive decline may be closely correlated with
the expression of tau. This study did indicate tau expression causes over excitation of γaminobutyric acid type A (GABAA), which causes seizures and death common among AD
patients. The relationship between tau and GABAA has been verified in other studies
(Andrews-Zwilling et al., 2010) with the removal of tau protecting against GABAA
impairment. Rapoport et al. (2002) also indicated tau is downstream of Aβ and is essential
to neurite degeneration. Furthermore, tau was identified to initiate continuous activity of
mitogen-activated protein kinase (MAPK) (Rapoport et al., 2002), which could provide
another link between increased levels of inflammation, apoptosis by caspase-3 and
oxidative stress.
Some of the aforementioned findings may not be contiguous with the human
development of AD as most use rodent models, which may express parts of the
pathogenesis. The following section will identify most commonly used rat models and their
specificity to AD development in comparison to human AD development. As well as
address the rodent model being used for this study and its specificity to the development
of AD.
The Rat Model of AD, TgF344-AD Closely Mimics Human Pathology
Most of the current transgenic rat models in use develop only portions of the AD
pathological cascade. The few models that express both an increased Aβ load and p-Tau
only form plaques without NFTs or NFTs without plaques (Kumar, & Singh, 2015).
However, the model we chose to address my hypotheses is the only model that expresses
both Aβ plaque formation and NFTs.
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Prior to the development of TgF344-AD, three rat models were commonly used:
UKUR25, Tg6590, and PSAPPTg478/Tg1116/Tg11587 (Do Carmo & Cuello, 2013). The
UKUR25 only expresses insoluble Aβ and p-tau with onset between 6 and 9m of age
(Echeverria et al., 2004; Vercauteren et al., 2004). Furthermore, insoluble Aβ has been
linked to neurotoxicity via hyperphosphorylated tau but does not form plaques (Echeverria
et al., 2004). This suggests that the AD like pathology does not develop in an age-dependent
manner because the development of the disease happens abruptly at a very young age. The
problem of early pathology development is due to cellular plasticity; cells are more viable
in younger models posing the possibility that cellular interactions are different among
youthful models compared to aged models. This may also eliminate the age-related decline
in physiological function and would not relate to the human model of AD development and
progression. Not that the findings from this model are irrelevant but the scope of the
findings from research using this model is very limited. By using this model, one may only
speculate on the actions of p-tau and not the full progression of the AD pathogenesis
involving both NFTs and plaques. The Tg6590 is another model for studying
cerebrovascular dysfunction and p-tau in an age dependent manner as these pathologies
develop around 15m and studies have cited some plaque formation (Folkesson et al., 2007;
Kloskowska et al., 2010). Cerebrovascular dysfunction is exhibited by Aβ cerebrovascular
deposits which produces toxic levels of NO and increases in p-tau leading to damaged
arteries resulting in loss in brain volume (Talantova et al., 2013). In this model
phosphorylated tau levels increase as age increases, whereas the previous model exhibits
abrupt induction of phosphorylated tau that does not increase with age. The TgF344-AD
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model captures all effects of the previously mentioned models and more in an age
dependent manner.
The TgF344-AD rat model has been demonstrated to develop plaques and NFTs
around 16m of age (Cohen et al., 2013) and the progression of this disease is age-dependent
and most similarly mirrors human development of AD (Cohen et al., 2013; Rorabaugh et
al., 2017). Very few studies have been published using this model to study AD
development but the research indicates trends in memory deficits and synapse dysfunction
between 6 and 16m of age (Cohen et al., 2013; Joo et al., 2017; Muñoz-Moreno et al., 2018;
Smith & McMahon, 2018; Pentkowski et al., 2018; Rorabaugh et al., 2017; Tsai et al.,
2014; Vorhees et al., 2018). Currently, none of the previous studies on this model have
used physiological tests like grip strength or rotarod (Panlab) to determine how muscle
strength and coordination are affected as AD develops in this model. Cohen et al. with the
use of the Barnes Maze Task (BMT), which is a learning and memory task used to measure
hippocampal function, saw a deficient trend in 6 month TgF344-AD rats. This study also
showed cerebral amyloid angiopathy (CAA)-like pathology progression at 6m but no
significant findings until the rat progressed to 15m of age (Cohen et al., 2013). If
decrements in muscle strength and function do occur prior to significant disease
development, these rats may exhibit significant losses in muscle strength and coordination
between 6 and 16m of age. A few studies have used the Morris Water Maze (MWM), which
measures memory to address hippocampal dysfunction much like the BMT. These studies
have mixed findings, which may in part be due to the differences in sample size.
Pentkowski et al. (2018) used 24 Tg rats vs 20 WT rats and found no significant findings
between the groups at 4-6m of age. Whereas, Rorabaugh et al. (2017) observed significant
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differences between the 6m old groups using a sample size of 6 WT and 6 Tg rats. As
reported by Cohen’s BMT in 6m old rats, there was a trend towards significance between
groups, 21 WT and 21 Tg rats. Muñoz-Moreno et al. (2018) also found a trend towards
significance using the delayed non-match-to-sample (DNMS) task at 6m with 9 WT and 9
Tg rats. Additionally, the few studies that have specifically examined the progression of
Aβ plaques, NFTs, and synapse dysfunction within this model do not identify significant
development of AD related symptoms until 9-16m old (Cohen et al., 2013; Joo et al., 2017;
Rorabaugh et al., 2017). Both Joo et al. (2017) and Smith and McMahon (2018) have
identified postsynaptic dysfunction starting at 9m but remain unchanged at 6m within this
model. These findings suggest significant changes to the brain start to appear within this
model at 9m yet the hallmarks (Aβ plaque and NFT) appear much later. Whether cognitive
impairment appears between 6-16m is still inconclusive, which makes this time point a
crucial age to determine whether cognitive function and muscular strength and function are
significantly different between the cohorts.
Significant Sex Differences are Present in the Development of AD
The divergence between sex and prevalence of AD is overwhelming, 78% of AD
cases are women (Alzheimer’s Association, 2018). Research has identified possible sex
differences across a wide array of variables from brain volume/composition differences,
hormonal response, epigenetic modifications and Aβ load. The difference in the
development of AD may stem from sexual differentiation and subsequent hormone
development in utero.
Carroll et al. (2010) analyzed sex differences in AD development among transgenic
AD adult mice and adult mice that were hormonally manipulated at the neonatal phase.
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Hormonal manipulation was carried out by demasculinizing males with androgen receptor
antagonist (flutamide) and defeminizing females with testosterone proprionate. The initial
findings indicated females expressed significantly higher Aβ loads in the frontal cortex at
both time points, whereas the males expressed no Aβ formation in this region. Furthermore,
both expressed significant increases in Aβ load in the hippocampus and subiculum but at
12m females expressed significantly higher expression in these regions. Other studies using
human models have suggested that sex hormones may influence circulating Aβ (Gandy et
al., 2001; Rosario et al., 2011). What’s more interesting about the Carroll et al. (2010)
study is that males performed significantly worse than the females on a hippocampal
dependent task at 6m but at 12m the females performed significantly worse than the males
on the same task. Irvine et al. (2012) identified a similar interaction among humans; males
performed significantly better on cognitive tests and that age and severity of dementia
could not explain the differences in performance between the sexes. To identify the role of
hormones on brain development Carroll et al. (2010) manipulated the hormonal state of
these neonatal transgenic mice by administering an androgen receptor antagonist to males
and testosterone propionate to females. At 7m of age, males showed significantly higher
Aβ loads in the hippocampus and subiculum with no effect on the frontal cortex. Females
expressed a significant decrease in Aβ load within the frontal cortex and increase in the
hippocampus with no effect in the subiculum. The results identify a modulating effect of
hormones on Aβ and brain development; furthermore, these hormones did not completely
oppose the results of natural transgenic adult model suggesting that brain development due
to sexual differentiation due to hormonal production begins in the embryonic stage. Based
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on these results and the positive correlation between aging and AD and negative correlation
between aging and hormone production suggests a hormonal impact on AD.
Nead et al. (2016) analyzed males with prostate cancer and their probability of
developing AD. This report revealed individuals using androgen deprivation therapy
significantly increased their risk in developing AD. Brain atrophy due to reduced sexhormones identified in this report was also confirmed in other studies (Leranth, Petnehazy,
& MacLusky, 2003; Woolley, & McEwen, 1992); one of which saw an association between
reduced dihydrotestosterone and brain derived neurotrophic factor (BDNF) due to aging
(Munetumo et al., 2015). BDNF has been cited to improve neuronal plasticity (Caldeira et
al., 2007; Garcia-Mesa et al., 2014). The same results are seen among females who
underwent hysterectomies, Phung et al. (2010) identified women were at greater risk of
developing AD the younger they were when the procedure was performed. The risk of AD
due to hysterectomies may be prevented by hormone treatment, as Henderson et al. (2005)
saw a significant decrease in AD risk among post-menopausal females between the ages
of 50-63 years old who used hormone treatment. However, the hormone treatment did not
reduce the risk of AD development among women older than 64, suggesting a window of
opportunity within hormone use. These reports identify that sex specific hormones can
promote the preservation of brain health and Rosario et al. (2011) confirmed the difference
in treatment is gender specific by analyzing the hormonal fluxes among men and women.
These reports identify the impact of sex hormones on brain health although how these
hormones specifically impact the rate and development of AD is still unclear. Recently
Burke et al. (2018) identified that women had greater percentage of hippocampus volume
relative to total brain volume compared to men. Additionally, the hippocampal volume
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ratio showed a significant relationship to the risk of developing MCI and progressing to
AD among women but not men (Burke et al., 2018). Among men, increases in white matter
hyperintensities were associated with increased rate of progression to MCI but not AD.
These studies explain why women may be more susceptible to AD and why their
progression is slower. Having higher Aβ loads that may be due to hormonal differences
can explain increased incidence of AD but by having more hippocampal volume provides
a buffer and allows for slower progression of AD. To help further explain how hormones
may impact the dichotomy of AD development researchers are narrowing the scope.
Bove et al. (2018) indicated that there is a relationship between the reproductive
period and epigenetic modifications at genes in the oxidative phosphorylation (OXPHOS)
pathway. Epigenetic modifications are heritable changes in gene expression absent of
changes to the genomic sequence (Verhoeven, Jansen, van Dijk and Biere, 2010). Among
the study participants, reproductive period was associated with epigenetic modifications in
both positive and negative directions depending on the gene region to OXPHOS-related
genes. Although the study did not link reproductive period with RNA expression or disease
outcome, it does point to a potential relationship between hormone exposure and DNA
methylation in the context of neurological morbidity and mortality. More work should be
done to understand if hormonal exposures throughout the reproductive period inhibit or
promote vulnerability to AD.
Purpose of the Research Study
As presented above, there is a clear relationship between exercise and brain health,
in fact, numerous studies have identified exercise as an activity that can enhance cognitive
function and attenuate brain atrophy. However, little is understood regarding the
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mechanisms behind the protection. This is in part due to the lack of an appropriate model
of AD, which may overcome with the newly developed TgF344-AD strain. This project
will provide the necessary first step in understanding the timeline of dysfunction present in
this strain by attempting to identify early changes in memory, motor coordination and
muscular strength. This is an essential first step in the discovery of the mechanisms of
exercise-induced protection against AD.
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CHAPTER THREE: MATERIALS AND METHODS
Animals
One male TgF344-AD rat and two female Fischer 344 rats were purchased from
the University of Southern California. Husbandry was carried out by Boise State University
(BSU) vivarium. At 3 weeks of age, animals were weaned and housed two per cage on a
12-h light/12-h dark cycle (light between 11pm and 11am). Food and water were available
ad libitum except during training and testing when they were outside of their cage. AD
genotyping was identified with ear tissue sampling. The samples were processed by
TransnetYX (Cordova, TN) and the results were withheld from the researchers until
experiment completion, 38 total animals (AD group: 12 males, 11 females, WT group: 8
males, 7 females). Animals were weighed and assessed every 3 m for 9 m; all procedures
were performed under the accordance of IACUC.
Skeletal Muscle Strength
Grip strength was assessed using the grip strength meter (Model GS3, Bioseb)
every 3 m to quantify the muscular strength of the animals. The device has a sampling rate
of 1000Hz allowing for the capture of short and low force peaks between 0 and 2kg.
Animals were held by the base of the tail and guided towards the device until the forelimbs
grasped the T-bar. The animals were gently pulled along the sensor axle until their grip
was released. Each animal completed two trials and were given a break between each trial
while their littermate was tested. Peak force was recorded and divided by bodyweight for
statistical analysis.
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Motor Coordination
Motor coordination was assessed using a Rota Rod (Model LE8305, Panlab). This
model contains 4 lanes with levers under each lane, time for each lane begins upon the
lever being raised. When the lever is depressed upon animal failure, the timer shows the
total rotating time as the end point for that animal. The motor ramp increases from 4 to 40
rpm, in this experiment the acceleration time was adjusted to 40 rpm/120 s. The animal
began the trial at 4 rpm with the rod reaching 40 rpm at 120 s. For this experiment, the
speed increased by 1 rpm every 3 s starting at 4 rpm. Each animal was given three trials
with a 2 min recovery between each trial; total time and maximum rpm was recorded for
each trial. Coordination was assessed based on how long (s) and at what speed (rpm) the
rat can stay on the Rota Rod. The best trial for each animal was used for statistical analyses.
Spatial Memory
The Morris Water Maze (MWM) procedure was used to assess the animal’s spatial
memory. A clear platform was placed in a cylinder pool with the water temperature at 26oC
(water temperature was maintained within 1 degree of this basal temperature). The platform
was placed in a fixed location close to the center of the pool; animals were placed in the
pool in four different quadrants. During the acquisition period, the platform was one inch
above the water surface and the animals were placed 3 times in each quadrant and given
60 s to find the platform. The animal was guided to the platform if it cannot locate the
platform in the allotted time. After each trial, the animals were given 10s to rest and to
become familiar with the platform location. The testing period used the same placement
strategy as the acquisition, however the platform was hidden. The water level was elevated
one inch above the platform and condensed milk was mixed into the water. The order of
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animal placement for both testing and acquisition was the same: starting at quadrant I
followed by II then III (which was opposite of II) then IV. Three trials for each quadrant
was recorded, if the animal did not reach the platform a score of 60s was given for that trial
and the animal was guided to the platform. Twelve trials total for each animal was recorded
for each time point (3, 6, and 9 m). Total time taken to complete MWM was averaged for
each animal and used for statistical analysis.
Data Analysis
A repeated measures ANOVA was used to identify change over time and a mixed
model 2-way ANOVA with a Bonferroni post hoc test was used to assess the effect of
group x age has on the outcome measures. A one-way analysis of variance (ANOVA) was
used to identify which variables contained significant findings. A Tukey post hoc test will
then be performed to identify significant group differences within the groups. Linear
regression and Pearson correlation was used to identify any correlations between the
variables. P values less than or equal to 0.05 will be considered statistically significant.
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CHAPTER FOUR: RESULTS
Results
Animals were housed with their same-gendered littermate for the whole study. All
animals tolerated the testing with no noticeable adverse effects to testing. One animal
developed an eye tumor at 3 m of age and another developed glaucoma at 6 m of age;
however, these animals were not removed from the study following veterinarian
examination. Post-acquisition period of the MWM, all animals learned the location of the
platform based on their ability to recall the platforms location during the first test period.
At 3 m, 6 m and 9 m, males were significantly heavier than females as illustrated
in Figure 1A (p<.05). Alzheimer’s disease (AD) males were significantly heavier than wild
type control (WT) males at 3 m (AD males: 360.3±26.3, WT males: 335.6±10.6, p<0.05)
but no significant difference in body weight was seen between AD females and WT
females (AD females: 211±12.3, WT females: 196.4±6.079, p > 0.05). AD males remained
significantly heavier weight than WT males at 6 m (AD males: 428.6±17.8, WT males:
408.4±12.1, p<0.05) and at 9 m (AD males: 462.6±22.7, WT males: 441.6±14.4, p<0.05).
AD females are significantly heavier than WT females at 6 m (AD females: 244.9±10.3,
WT females: 223.4±5.2, p<0.0001) and 9 m (AD females: 255.4±9.3, WT females:
233±5.8, p<0.0001). Differences between female groups are illustrated in Figure 1B and
males are illustrated in Figure 1C. There was no significant difference among body weight
at any time point between the AD or WT group as a whole. Repeated measures ANOVA
revealed a significant change in body weight at between 6 and 9 m among all groups
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(p<0.05). Mixed model 2-way ANOVA (group x age) identified groups WT, AD, WT male
and AD male and age show significant effect for body weight at 9 m but no interaction was
seen between group and age. Changes in WT and AD body weight are displayed in Table
1.
Table 1.
3m

Body Weight (g)
6m
β

β

WT β significantly
271±72
322±96 than
344±108
73
Note.
different
3 m (p<0.05)

AD

289±79

341±95β

3m

6m

9m

Δ

WT Fem

196±6

223±5β

233±6β

37

WT Male

336±11

408±12β

442±14β

106

AD Fem

211±12

245±10β

255±9β

44

AD Male

360±26

429±18β

463±23β

103

Δ

9m

364±107β

75

Note. β significantly different than 3 m (p<0.05)
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Figure 1.
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Figure 1. A) Males are significantly heavier than females at each time point and all groups begin to
display significant heavier body weight at 6 m, which continues through 9 m. B) AD females exhibit
significantly heavier body weight at 6 m and 9 m compared to WT females. C) AD males exhibit
significantly heavier body weight at 3 m, 6 m, and 9 m compared to WT males.
β significantly different than 3 m (p<0.05)
# significantly different than WT female (p<0.05)
γ significantly different AD females (p<0.05)
@ significantly different than WT male (p<0.05)

Among grip strength, WT females recorded higher peak force relative to body
weight than WT males at 3 m (WT female: 3.94±0.552, WT male: 2.86±0.525, p=0.0019)
and 9m (WT female: 4.71±0.59, WT male: 3.33±0.58, p=0.0005). As depicted in Figures
2A and 2B no difference was seen between these two groups at 6 m (WT female:
4.27±0.92, WT male: 3.04±1.03, p > 0.05). AD females also express significantly higher
peak force relative to body weight AD males at all three time points; 3 m (AD female:
4.61±0.88, AD male: 3.11±0.77, p<0.001), 6 m (AD female: 4.28±1.03, AD male:
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2.58±0.83, p<0.001), and 9 m (AD female: 4.83±0.66, AD male: 3.08±0.7, p<0.0001).
The differences between AD groups are displayed in Figures 2A and 2C. There is no
significant difference in grip strength between AD females and WT females or AD males
and WT males at any time point. No significant differences were seen between AD and
WT at any time point. The change in grip strength over time was not significant for any
group, and there was no interaction between genotype or age and grip strength. Table 2
illustrates changes in grip strength over time for the WT and AD groups.
Table 2.
WT

AD

Grip Strength

3m

6m

9m

Δ

3.4±0.8

3.7±1

4±0.9

0.6

3.8±1.1

3.5±1.2

3.9±1.1

0.1

3m

6m

9m

Δ

WT Fem

3.9±0.6

4.3±0.8

4.7±0.6

0.8

WT Male

2.9±0.5

3.1±0.9

3.3±0.6

0.4

AD Fem

4.6±0.9

4.3±1

4.8±0.7

0.2

AD Male

3.1±0.8

2.7±0.7

3.1±0.7

0

Note. No significant changes over time were seen among any groups
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Figure 2. A) AD females express significantly higher grip strength than AD males at each time point.
WT females express significantly higher grip strength than WT males at 3 m and 9 m. B) WT females
express significantly higher grip strength than WT males at 3 m and 9m. C) AD females express
significantly higher grip strength than AD males at each time point.
@ significantly different than WT male (p<0.05)
Ω significantly different than AD male (p<0.05)

Similar to grip strength both female groups exhibited significantly better
performances on the rotarod than their male cohort, which is illustrated in Figure 3B. At 3
m WT females indicated significantly higher motor coordination than WT males (WT
female: 71.7±23.5, WT male: 47.6±12.2, p<0.05) and remained significant at 6 m (WT
female: 58.6±20.6, WT male: 33.5±9.3, p<0.01) and 9 m (WT female: 45±13.4, WT male:
23.6, p<0.01) as seen in Figure 3C. AD Females display significantly better motor
coordination than AD males at 3 m (AD female: 71.2±17, AD male: 51.17±15.09, p<0.01)
and 9 m (AD female: 35.36±12.76, AD male: 26±5.22, p<0.01), but at 6 m there was no
significant difference in performance (AD female: 48.4±13.6, AD male: 41±8.5, p > 0.05).
The differences between the AD genders and rotarod task is shown in Figure 3D. Repeated
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measures identified significant change among AD females, AD males, WT and AD group
in rotarod performance from 3 to 6 m (p<0.01) and all groups displayed a significant
decline from 3 m to 9 m (p<0.05). No significant differences were found between AD vs.
WT. 2-way ANOVA revealed AD females, AD group and age had a significant effect of
at 6m (p<0.01) and all groups by 9 m (p<0.05). The significant decline in rotarod
performance among the WT and AD groups are illustrated in Figures 3A, 3B and Table 3.
Table 3.

WT

AD

Rotarod (s)

3m

6m

9m

Δ

59±22

45±20

34±16β

-25

61±19

45±12β

31±11β

-30

Note. β significantly different than 3 m (p<0.05)

3m

6m

9m

Δ

WT Fem

72±24

59±21

45±13β

-27

WT Male

48±12

34±9

24±10β

-24

AD Fem

71±17

48±14β

35±13β

-36

AD Male

51±15

41±9β

26±5β

-25
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Figure 3.
WT
AD

Time (s)

60

β
β

40

RotaRod
B) 100
80
Time (s)

A) 80

20

β@

60

βΩ@

WT Female
WT Male
AD Female
AD Male

40
20

0

0
3

6

WT Female
WT Male

@

3

9

Months

C) 100
80

Ω@

80

6

9

Months

D) 100

AD Female
AD Male

Ω

60

@

40
20

Time (s)

Time (s)

@
60
Ω

40
20

0

0
3

6

Months

9

3

6

9

Months

Figure 3. A) Both AD and WT group’s significantly declined in rotarod performance at 6 m and 9 m.
B) WT females display significantly better rotarod performance than WT males at each time point.
AD females display significantly better rotarod performance than AD males at 3 m and 9 m. Both AD
females and AD males significantly declined in rotarod performance at 6 m and all groups
significantly declined in performance at 9 m. C) WT females display significantly better rotarod
performance than WT males at each time point. D) AD females display significantly better rotarod
performance than AD males at 3 m and 9m.
@ significantly different than WT male (p<0.05)
Ω significantly different than AD male (p<0.05)
β significantly different than 3 m (p<0.05)

Using the Morris Water Maze to assess memory, no group displayed significantly
different performances from each other at 3 m (WT female: 17.9±12.3, AD female:
25.5±13.4, WT male: 22.5±19.5, AD male: 25.6±13.7, p > 0.05). At 6 m males did not
display statistically different means (WT male: 22.75±14.43, AD male: 22.27±14.03, p >
0.05). However, Figure 4C shows WT females displayed significantly better memory
function than AD females at 6 m (WT female: 15.3±10.7, AD female: 24.5±16.1, p<0.01.
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At 9m significance between females was lost but the WT females performed significantly
better than AD males (WT female: 12.2±6.4, AD male: 23.16±14.46, p<0.0001), whereas
AD females (20.9±15) and WT males (19.2±15.8) were not significantly different. The
differences between genders are illustrated in Figure 4B. There was no significant
difference between WT and AD at 3 m or 6 m but by 9 m the AD group displayed
significantly longer time to reach the platform than WT (AD: 22.1±14.7, WT: 15.9±12.7,
p<0.01). The significant difference between WT and AD groups at 9 m are shown in Figure
4A. No group expressed a statistically significant change in performance from 3 m to 6 m
or 9 m but these groups express negative trend over time on this task, which is displayed
in Table 4.
Table 4.
WT

AD

Morris Water Maze (s)

3m

6m

9m

Δ

20±16

19±13

16±13

-4

26±13

23±15

22±15

-4

3m

6m

9m

Δ

WT Fem

18±12

15±11

12±6

-6

WT Male

23±20

23±14

19±16

-4

AD Fem

26±13

25±16

21±15

-5

AD Male

26±14

22±14

23±16

-3

Note. No significant change over time were seen among any groups
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Figure 4.
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Figure 4. A) AD group displayed significantly worse performance at 9 m compared to WT group. B)
AD males took significantly longer than WT females to find the platform at 9m. C) AD females took
significantly longer than WT females to find the platform at 6 m.
# significantly different than WT female (p<0.05)

After running a linear regression and Pearson correlation age and body weight
exhibited strong correlation to one another and the rotarod task, which measures motor
coordination. Age and body weight displayed a strong positive correlation to each other
among all groups (WT female: r = 0.9126, p < 0.0001; WT male: r = 0.9455, p < 0.0001;
AD female: r = 0.8421, p < 0.0001; AD male: r = 0.8753, p < 0.0001). The correlation
between body weight and rotarod performance indicated a moderate but significantly
negative correlation among WT females (r = -05924, p<0.005), WT males (r = -0.7443,
p<0.0001), AD females (r = -0.6865, p<0.0001), and AD males (r = -0.6375, p<0.0001).
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WT females were the only group to have a significant correlation between body weight
and MWM (r = -0.4631, p = 0.0459), as well as, age and grip strength (r = 0.4345, p<0.05).
Age and rotarod performance also displayed a moderate to high negative correlation among
all groups: WT female (r = -0.5145, p<0.05), WT males (r = -0.7068, p<0.0001), AD
females (r = -0.72, p<0.0001) and AD males (r = -0.7144, p<0.0001).
The AD group and WT group expressed similar correlations, body weight among
both groups showed a negative correlation to grip strength (WT: r = -0.5271, p<0.001, AD:
r = -0.6769, p<0.0001) and rotarod performance (WT: r = -0.6859, p<0.0001, AD: r = 0.5110, p<0.0001). Age and rotarod performance expressed a negative correlation between
these two groups as well (WT: r = -0.4864, p<0.001, AD: r = -0.6674, p<0.0001) but no
significant correlations were found between age grip strength.
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CHAPTER FIVE: DISCUSSION
This is the first study to characterize early changes in body weight, muscular
strength, motor coordination and memory within the TgF344-AD model. The major
finding of this study was TgF344-AD rats displayed significantly impaired memory at 9 m
compared to WT control. This indicates that memory dysfunction occurs prior to
significant plaque and NFT accumulation, as previous work with this model showed no
significant accumulation at 9 m and significant accumulation by 15 m (Cohen et al., 2013;
Rorabaugh et al., 2017). However, because this study did not analyze AD pathology at any
time, changes seen in memory, body weight, and coordination cannot be attributed to AD
pathology. In addition, at 12 m animals were not yet showing signs of decreased muscular
strength and coordination. These findings confirm that memory decline occurs prior to
muscular strength and coordination decline, but motor coordination declines at a faster rate
among rodents with AD in this study. Finally, AD may cause early weight gain among both
males and females, which was an unexpected result, requiring further research.
TgF344-AD rats display memory dysfunction at 9 m. The Morris water maze was
used to assess memory and the results suggest that memory dysfunction occurs before
strength and motor decline among the rodents expressing AD. According to previous
studies on the TgF344-AD model, memory dysfunction reported here occurs months before
appreciable plaque and NFT development, which is expressed between 15-19 m (Cohen et
al., 2013; Rorabaugh et al., 2017; Tsai et al., 2013). Previous literature using this task to
measure memory indicates that swim speed does not differ between groups at 6 or 16 m
(Rorabaugh et al., 2017), which is why swim speed was not accounted for in this report.
Memory dysfunction prior to the onset of AD seen in this study is supported by literature
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investigating this TgF344-AD and the human model (Muñoz-Moreno et al., 2018;
Rorabaugh et al., 2017). The timeline for decline in strength and motor coordination is still
unknown for this model.
Early synapse dysfunction in the locus coeruleus and hippocampus not Aβ plaques
or NFTs caused the early memory dysfunction. As stated previously there is still a debate
between whether physiological declines precedes AD pathology but this report indicates
that memory dysfunction occurs prior to any significant physiological decline or plaque
and NFT build-up (Cohen et al. 2013). Other investigations on the TgF344-AD model of
AD progression have revealed significant synapse dysfunction and hyperphosphorylated
tau in the locus coeruleus by 6 m and a decrease in connectivity in the hippocampus by 9
m (Rorabaugh et al., 2017; Smith & McMahon, 2018), which may cause the memory
dysfunction seen at 9 m in the AD group in this study. Smith and McMahon indicated that
altered synaptic activity becomes significantly present in the hippocampus of males at 9m
and the females by 12 m. Although this study did not find a significant difference in
memory between AD females and males at 9 m, AD males show a positive trend by 9 m,
whereas the females remain negatively trending. Sex differences in memory decline are
still unknown to exist in this model but may occur prior to 15 m age in the current model.
Future research should analyze synapse dysfunction and other AD related pathology to
elucidate the cause of memory dysfunction occurring at this early time point.
No significant sex differences were seen in memory dysfunction. Previous studies
support a sex difference in memory decline, suggesting males exhibit an earlier and more
drastic decline in memory and females experience a slow but steady decline (Carroll et al.,
2010). This may be due to females having higher percent hippocampus volume compared
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to males, which may be the result of slower progression of AD symptoms in females (Burke
et al., 2018). Yet no sex differences have been revealed at these time points in memory
dysfunction, which may be more present later. To elucidate sex differences that are
relatable to the human model, future research should identify brain volume differences and
memory decline between 6 m and 15 m among the TgF344-AD model. WT females were
the only group to express a negative correlation between body weight and MWM
performance. However, studies have yet to be carried out to assess the correlation between
body weight and memory. Furthermore, body composition was not accounted for so
inferences on lean mass or adipose tissue impacting memory cannot be made. More
research is needed to assess the correlation between body weight/body composition and
memory to better understand why this relationship may exist.
AD does not significantly impact early motor coordination because all AD and WT
groups expressed a decline in performance on this task, which was not significantly
different at any time. Motor coordination and strength share a close relationship (Sheppard,
& Young, 2006), for example, if motor coordination is declining strength should be
declining as well but the results indicate the opposite has occurred. The early decline in
motor coordination is a result of a Fischer 344 background and using the rotarod task to
assess motor coordination. Previous studies have indicated that Fischer 344 rats typically
express early declines in the rotarod task prior to declines in strength (Shukkit-Hale,
Mouzakis, & Joseph, 1998). This indicates that the assessment of motor coordination using
the rotarod may not give a true account of Fischer 344 motor coordination abilities. Other
studies have used alternative motor coordination tasks along with the rotarod task on
Fischer 344 rats and found motor coordination on the alternative tasks decline later at a
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slower rate and follow declines in strength (Shukkit-Hale et al., 1998). An alternate motor
task or an alteration to the rotarod task should be considered when measuring motor
coordination on the rodent model TgF344-AD.
Body weight may have caused the decline in motor coordination. The decline in
rotarod performance shows a moderate to high negative correlation to age and body weight
among all groups. Salvatore et al. (2016), study suggests that body weight may have a
significant impact on rotarod performance for Fischer 344 rats as caloric restriction
prevents early decline in motor coordination as measured by the rotarod (Salvatore et al.
2016). However, AD females and the AD group as a whole showed a significant decline in
motor coordination by 6 m, whereas the other groups began expressing a significant decline
from their baseline at 9 m. AD females showed significantly higher body weight at 6 m
compared to WT females which may have resulted in the significant decline in motor
coordination at 6 m. Since the AD group also indicated a significant decline at 6 m body
weight differences cannot fully explain this decline.
AD may accelerate age related motor neuron cycling. The early decline in
performance may be a result of AD, previous studies have seen synapse dysfunction,
increases in microglia activity and hyperphosphorylated tau by 6 m, but brain atrophy
caused by plaques and NFTs do not become significantly present until 15 m at in the
TgF344-AD model (Cohen et al., 2013; Muñoz-Moreno et al.,2018; Rorabaugh et al.,
2017; Smith, & McMahon, 2018). If this enhanced rate of motor decline is caused by AD,
this may be a result of motor neuron alterations. As stated previously, AD progresses with
age and age showed a negative correlation with the rotarod task. Research has shown that
motor neurons cycle through denervating and reinnervating motor units causing a
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restructuring of that motor unit each time which may enhance muscular atrophy (Baloh,
Rakowicz, Gardner, & Pestronk, 2007; Butikofer, Zurlinden, Bollinger, Kunz, &
Sonderegger,

2011; Holloszy, & Larson, 1995). Since AD is a CNS disorder and

progresses with age, it is likely AD may impact motor units by enhancing motor neuron
innervation cycling or by disrupting neural output to the periphery. Currently no research
has investigated AD impact on motor neurons but AD does share commonalities between
other brain diseases that impact motor control like Parkinson’s disease (Forloni, Artuso,
La Vitola, & Balducci, 2016; Maple-Grødem et al., 2018). Since AD has been implicated
in increased muscle loss and early strength and motor coordination deficits (Boyle et al.,
2010; Davatzikos et al., 2011), AD may impact these symptoms by altering motor neuron
activity; however, no research has analyzed whether AD has an impact on motor neurons.
If AD impacts motor neurons it is likely to see motor coordination deficits prior to strength
deficits because muscles used for coordinated movements require more motor units per
muscle volume, which means more motor neurons per fiber. Future research should
investigate how AD may impact the peripheral nervous system during preclinical and
clinical stages of AD, specifically in muscles used for fine motor movements.
AD did not affect muscular strength in early and mid-life animals. There was no
significant difference in grip strength or change in grip strength other than both female
groups displayed greater grip strength relative to body weight compared to their male
cohorts. Suggesting that AD does not impact grip strength prior to memory loss among
familial AD cases. These results contradict some of the literature investigating baseline
strength and risk of developing of AD, which indicate lower baseline strength may be a
pre-onset symptom of AD (Buchman et al., 2007a,b). However, some sources do indicate
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memory loss precedes muscular based declines (Taekama et al., 2012), which is supported
by the present findings. Although the literature is mixed on this topic as early declines in
muscular strength may be more relatable to sporadic AD compared to familial AD because
familial AD comprises only 5% of all AD cases (Alzheimer’s Association, 2018) and
TgF344-AD represents familial AD development and progression. Nonetheless, future
research should investigate whether grip strength declines prior to significant plaque and
NFT formation using this model. Identifying possible physiological changes prior to
irreversible damage caused by AD may provide a window of opportunity for preventing or
moderating AD.
Weight gain was similar between WT and AD groups as there was no significant
difference expressed between these two groups at any time. All groups displayed
significant weight gain by 6 and 9 m but this significant increase in weight may be due to
sex differences because only WT males and AD males expressed a significant effect for
body weight by 9 m. The significant gain in weight exhibited by males from baseline is a
sex difference due to physiological differences in aging and not due to the sex differences
that may exist in the early development of AD, as aging and body weight showed a strong
positive correlation in the present study.
AD effects weight gain among females and males. Both AD males and females
expressed significantly heavier body weight than their cohort indicating that AD may have
an impact on weight gain. Midlife obesity is correlated to the risk of developing dementia
and AD (Kivipelto et al., 2005). However, the present study cannot indicate whether the
weight gain was due to an increase in lean mass but the results support the role AD has on
weight gain when analyzing the groups separated by sex. Other studies have indicated
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humans suffering from AD experience significant body weight fluctuations compared with
normal aging (White, Pieper, Schader, & Fillenbaum 1996; Beydoun et al., 2008).
Furthermore, research suggests that underweight males and overweight females between
30 and 50 years old are at higher risk of developing AD (Beydoun et al., 2008).The current
study does not show that these weight fluctuations between the sexes occur but these this
model is still in the preclinical AD stage, whereas the previous studies analyzed data from
individuals during AD. Weight change due to sex may not occur in this model of AD but
the results do support previous work indicating AD may cause early weight gain. Future
research should analyze body composition and food intake to understand why heavier
weights were seen among AD animals.
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CONCLUSION
Memory dysfunction in TgF344-AD occurs at 9 m, prior to significant loss in
strength and coordination compared to the WT cohort. There was no significant differences
in strength or motor coordination between WT or AD groups indicating AD does not
significantly impact physiological parameters prior to memory deficits. No clear sexdifferences were seen in the early development of AD. However, AD males begin to show
a positive trend in the memory task by 9 m, whereas the AD females and WT groups
continue to show a negative trend. Additionally, females at risk for AD may express a
higher rate motor coordination decline prior to clinical diagnoses. Taken together, the
results confirm memory deficits occur during the preclinical phase of AD and further
suggest that memory tests may be more sensitive to males, whereas motor coordination
tests may be more sensitive for females. Additionally, higher body weights may be an early
sign for at risk individuals.
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Figure A.1

Amyloid Cascade Hypothesis
Hardy & Selkoe (2002).

